ANI Pharmaceuticals (ANIP) News Today $58.16 -0.19 (-0.33%) Closing price 04:00 PM EasternExtended Trading$58.18 +0.02 (+0.03%) As of 05:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Wedge Capital Management L L P NC Reduces Stock Position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)Wedge Capital Management L L P NC decreased its position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 45.1% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 32,216 shares of the specialty pharmaceutical comJanuary 21 at 3:24 AM | marketbeat.comANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Receives Consensus Recommendation of "Buy" from AnalystsShares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Get Free Report) have been given a consensus rating of "Buy" by the eight brokerages that are currently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a hold rating, six have assigned a buy ratingJanuary 21 at 2:14 AM | marketbeat.comANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Sees Large Drop in Short InterestANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Get Free Report) was the target of a large decrease in short interest in December. As of December 31st, there was short interest totalling 2,150,000 shares, a decrease of 8.5% from the December 15th total of 2,350,000 shares. Based on an average daily trading volume, of 252,300 shares, the short-interest ratio is currently 8.5 days.January 18, 2025 | marketbeat.comAssenagon Asset Management S.A. Buys 125,438 Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)Assenagon Asset Management S.A. raised its stake in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 67.4% during the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 311,617 shares of the specialty pharmaceutical company's stock after pJanuary 18, 2025 | marketbeat.comANI Pharmaceuticals (ANIP) Receives a Buy from Raymond JamesJanuary 17, 2025 | markets.businessinsider.comANI Pharmaceuticals (NASDAQ:ANIP) Stock Quotes, Forecast and News SummaryJanuary 16, 2025 | benzinga.comLeerink Partners Keeps Their Buy Rating on ANI Pharmaceuticals (ANIP)January 15, 2025 | markets.businessinsider.comANI Pharmaceuticals, Inc. (NASDAQ:ANIP) VP Meredith Cook Sells 400 SharesJanuary 14, 2025 | insidertrades.comANI Pharmaceuticals sees FY25 revenue $739M-$759M, consensus $720.3MJanuary 14, 2025 | markets.businessinsider.comInsider Selling: ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) VP Sells 400 Shares of StockANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Get Free Report) VP Meredith Cook sold 400 shares of ANI Pharmaceuticals stock in a transaction dated Monday, January 13th. The shares were sold at an average price of $53.92, for a total value of $21,568.00. Following the completion of the sale, the vice president now directly owns 55,588 shares in the company, valued at $2,997,304.96. This represents a 0.71 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.January 13, 2025 | marketbeat.comANI Pharmaceuticals, Inc.: ANI Pharmaceuticals Provides Preliminary Fourth Quarter and 2024 Financial Results and Preliminary 2025 OutlookJanuary 13, 2025 | finanznachrichten.deANI Pharma Expects FY24 Adj. EPS, Total Net Revenues To Meet Or Exceed OutlookJanuary 13, 2025 | markets.businessinsider.comAlcami Announces CEO TransitionJanuary 13, 2025 | prnewswire.comANI Pharmaceuticals (NASDAQ:ANIP) Hits New 1-Year Low - Here's What HappenedANI Pharmaceuticals (NASDAQ:ANIP) Sets New 1-Year Low - Here's WhyJanuary 13, 2025 | marketbeat.comANI Pharmaceuticals Provides Preliminary Fourth Quarter and 2024 Financial Results and Preliminary 2025 OutlookJanuary 13, 2025 | globenewswire.comJPMorgan Chase & Co. Has $33.10 Million Stock Holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)JPMorgan Chase & Co. raised its stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 159.3% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 554,835 shares of the specialty pharmaJanuary 7, 2025 | marketbeat.comANI Pharmaceuticals, Inc.: ANI Pharmaceuticals Announces the FDA Approval and Launch of Prucalopride Tablets with 180-Day CGT ExclusivityJanuary 2, 2025 | finanznachrichten.deANI Pharma Launches FDA-Approved Prucalopride Tablets With 180-Day CGT ExclusivityJanuary 2, 2025 | markets.businessinsider.comANI Pharmaceuticals launches Prucalopride Tablets after FDA approvalJanuary 2, 2025 | markets.businessinsider.comANI Pharmaceuticals Announces the FDA Approval and Launch of Prucalopride Tablets with 180-Day CGT ExclusivityJanuary 2, 2025 | globenewswire.comANI Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceDecember 30, 2024 | globenewswire.comANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Short Interest Up 27.7% in DecemberANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Get Free Report) was the recipient of a large growth in short interest in the month of December. As of December 15th, there was short interest totalling 2,350,000 shares, a growth of 27.7% from the November 30th total of 1,840,000 shares. Based on an average daily trading volume, of 253,300 shares, the days-to-cover ratio is presently 9.3 days.December 29, 2024 | marketbeat.comANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Shares Acquired by Geode Capital Management LLCGeode Capital Management LLC boosted its holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 4.2% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 425,225 shares of the specialty pharmaceutical companyDecember 28, 2024 | marketbeat.comWellington Management Group LLP Lowers Holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)Wellington Management Group LLP lowered its position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 78.4% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 9,411 shares of theDecember 21, 2024 | marketbeat.comState Street Corp Acquires 58,698 Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)State Street Corp raised its position in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 9.1% during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 703,843 shares of the specialty pharmaceutical companDecember 21, 2024 | marketbeat.comANI Pharmaceuticals, Inc. (NASDAQ:ANIP) CFO Sells 7,500 SharesDecember 19, 2024 | insidertrades.comStephen P. Carey Sells 7,500 Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) StockANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Get Free Report) CFO Stephen P. Carey sold 7,500 shares of the company's stock in a transaction that occurred on Tuesday, December 17th. The stock was sold at an average price of $55.79, for a total transaction of $418,425.00. Following the transaction, the chief financial officer now directly owns 154,468 shares of the company's stock, valued at $8,617,769.72. This trade represents a 4.63 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.December 18, 2024 | marketbeat.comBarclays PLC Purchases 135,003 Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)Barclays PLC grew its position in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 1,681.2% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 143,033 shares of the specialty pharmaceutical company's stockDecember 18, 2024 | marketbeat.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Decreases Stock Holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC reduced its position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 21.0% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 33,951 shares of the specialtDecember 16, 2024 | marketbeat.comANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Short Interest Down 12.8% in NovemberANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Get Free Report) was the target of a significant decrease in short interest during the month of November. As of November 30th, there was short interest totalling 1,840,000 shares, a decrease of 12.8% from the November 15th total of 2,110,000 shares. Based on an average daily volume of 292,900 shares, the days-to-cover ratio is currently 6.3 days.December 15, 2024 | marketbeat.comANI Pharmaceuticals, Inc. (NASDAQ:ANIP) SVP Sells $60,000.00 in StockDecember 13, 2024 | insidertrades.comLeerink Partnrs Upgrades ANI Pharmaceuticals (NASDAQ:ANIP) to "Strong-Buy"Leerink Partnrs raised shares of ANI Pharmaceuticals to a "strong-buy" rating in a research report on Wednesday.December 12, 2024 | marketbeat.comLeerink Partners Initiates Coverage of ANI Pharmaceuticals (ANIP) with Outperform RecommendationDecember 12, 2024 | msn.comANI Pharmaceuticals (NASDAQ:ANIP) Coverage Initiated by Analysts at Leerink PartnersLeerink Partners assumed coverage on shares of ANI Pharmaceuticals in a research report on Wednesday. They set an "outperform" rating and a $80.00 price objective on the stock.December 11, 2024 | marketbeat.comCharles Schwab Investment Management Inc. Buys 8,869 Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)Charles Schwab Investment Management Inc. lifted its position in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 3.7% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor oDecember 8, 2024 | marketbeat.comHotchkis & Wiley Capital Management LLC Purchases New Shares in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)Hotchkis & Wiley Capital Management LLC purchased a new position in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 52,080 shares of the specialtyDecember 7, 2024 | marketbeat.comANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Receives Average Rating of "Moderate Buy" from BrokeragesANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Get Free Report) has received a consensus rating of "Moderate Buy" from the six research firms that are presently covering the company, Marketbeat reports. One research analyst has rated the stock with a hold rating and five have issued a buy rating on thDecember 2, 2024 | marketbeat.comMartingale Asset Management L P Grows Stock Holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)Martingale Asset Management L P grew its holdings in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 65.3% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 34,740 shares of the specialty pharmDecember 1, 2024 | marketbeat.comBank of Montreal Can Makes New $13.04 Million Investment in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)Bank of Montreal Can purchased a new stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 221,896 shares of the specialty pharmaceutical company's stock, valuDecember 1, 2024 | marketbeat.comIntech Investment Management LLC Takes Position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)Intech Investment Management LLC bought a new position in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) in the third quarter, according to the company in its most recent filing with the SEC. The fund bought 12,593 shares of the specialty pharmaceutical company's stock, valued at aNovember 30, 2024 | marketbeat.comANI Pharmaceuticals (NASDAQ:ANIP) Shares Down 2.9% - Here's What HappenedANI Pharmaceuticals (NASDAQ:ANIP) Trading Down 2.9% - Should You Sell?November 29, 2024 | marketbeat.comInsider Selling: ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) CEO Sells 33,481 Shares of StockNovember 28, 2024 | insidertrades.comRubric Capital Management LP Lowers Position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)Rubric Capital Management LP decreased its position in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 90.6% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 56,671 shares of the specialty pharmaceNovember 27, 2024 | marketbeat.comANI Pharmaceuticals to Present at 36th Annual Piper Sandler Healthcare ConferenceNovember 26, 2024 | globenewswire.comEagle Asset Management Inc. Purchases New Shares in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)Eagle Asset Management Inc. acquired a new position in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 35,630 shares of the specialty pharmaceutiNovember 26, 2024 | marketbeat.comANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Shares Acquired by Pacer Advisors Inc.Pacer Advisors Inc. lifted its stake in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 23,259.8% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 568,343 shares of the specialty pharmacNovember 23, 2024 | marketbeat.comThompson Siegel & Walmsley LLC Has $13.73 Million Stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)Thompson Siegel & Walmsley LLC increased its holdings in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 17.6% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 230,159 shares of theNovember 21, 2024 | marketbeat.comANI Pharmaceuticals Advances Amidst Regulatory and Market ChallengesNovember 21, 2024 | markets.businessinsider.comGlobal Alpha Capital Management Ltd. Has $32.01 Million Stock Holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)Global Alpha Capital Management Ltd. raised its holdings in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 1.8% in the 3rd quarter, according to its most recent 13F filing with the SEC. The fund owned 536,450 shares of the specialty pharmaceutical company's stock after acquiringNovember 20, 2024 | marketbeat.comANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Sees Significant Growth in Short InterestANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Get Free Report) was the target of a significant increase in short interest in the month of October. As of October 31st, there was short interest totalling 2,160,000 shares, an increase of 5.4% from the October 15th total of 2,050,000 shares. Based on an average daily volume of 310,500 shares, the days-to-cover ratio is presently 7.0 days.November 17, 2024 | marketbeat.com Get ANI Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ANIP and its competitors with MarketBeat's FREE daily newsletter. Email Address ANIP Media Mentions By Week ANIP Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ANIP News Sentiment▼0.910.64▲Average Medical News Sentiment ANIP News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ANIP Articles This Week▼75▲ANIP Articles Average Week Get ANI Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ANIP and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies TG Therapeutics News Axsome Therapeutics News Krystal Biotech News Verona Pharma News Organon & Co. News Scholar Rock News Alvotech News Biohaven News ADMA Biologics News Apellis Pharmaceuticals News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ANIP) was last updated on 1/22/2025 by MarketBeat.com Staff From Our PartnersMedia Humiliated: Demo of Elon’s Tech Proves They’re WrongElon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is ...Brownstone Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredDid You See Trump’s Manhattan Project Bombshell?This secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredKamala’s final humiliation Now, for the first time, I’m going to share these ten investments publicly – the same ones I’ve discussed behi...Porter & Company | SponsoredJanuary 29th - the next big trading catalyst to watch Mark your calendar for January 29th. Because on that day, I believe we could see a $2 Trillion shock INTO t...Timothy Sykes | SponsoredElon’s #1 AI Stock” SET TO SOARForget ChatGPT! Because Elon Musk's AI promises to be 100x more powerful.Behind the Markets | SponsoredMust-See: 5-Second Trump PredictionPresident Trump's prediction is about to become a reality... Opening a rare window of opportunity for you t...InvestorPlace | SponsoredNvidia’s Bold Move: Tackling Tech’s $1 Trillion CrisisTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ANI Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ANI Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ANIP Stock Alerts